Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 2% increase in its share price over the past week as the company announced promising initial results from the Phase 1b LINKER-MM2 trial related ...

The EC has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic for treating multiple myeloma.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our ... with relapsed/refractory (“R/R”) multiple myeloma (“MM”); the likelihood, timing ...

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.

The Food and Drug Administration is reviewing the biologics licence application for the antibody in the US, with a decision expected by 10 July 2025. Regeneron Pharmaceuticals president ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab) has been granted conditional marketing approval by the European Commission (EC) to treat relapsed and refractory (R/R) multiple myeloma (MM).

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...

The introduction of new agents immunomodulatory drugs (IMiDs) and proteasome inhibitors ... treatment of newly diagnosed and refractory multiple myeloma (MM). Thalidomide was the first ...

Multiple myeloma forms in blood plasma cells within bone marrow, affecting 2000 Australians a year. About 1500 of those are ineligible for stem cell transplantation – the standard treatment.